# Case-001 Branch Review Minimum Packet Gate

Date checked: 2026-06-25
Status: private packet readiness map, not treatment advice

## Direct Answer

The branch question is ready as a question, but the public repo cannot say the
private packet is ready. Before a hematologist can usefully answer branch scope,
six private packet domains need owner review.

Current operational label:

`case001_branch_review_packet_not_ready_public_only`

## Minimum Packet Domains

| Domain | Why it matters for branch review | Public label if missing |
| --- | --- | --- |
| Diagnosis, genotype, phenotype | Branch relevance depends on confirmed disease type and molecular context. | `missing_diagnosis_genotype_phenotype` |
| Transfusion burden and response | TDT severity and response pattern frame standard-care and advanced-therapy discussion. | `missing_transfusion_burden_response` |
| Blood-bank and immune history | Alloantibodies, DAT, reactions, matching, and spleen context affect stabilization and risk. | `missing_blood_bank_immune_history` |
| Iron, organ-risk, chelation status | Liver iron, cardiac `T2*`, ferritin trend, organ risk, and chelator safety shape timing and branch risk. | `missing_iron_organ_chelation_status` |
| HCT/gene-cell access context | HLA/donor, center, payer, geography, fertility counseling, and travel constraints decide whether a branch is even discussable. | `missing_hct_gene_cell_access_context` |
| Consent, ethics, owner review | Private records and consequential routing require family/clinician owner handling. | `missing_consent_ethics_private_owner_review` |

## Doctor Handoff Question

Once the private packet is complete enough for review, ask:

> Are any domains still missing before you can answer whether Case-001 belongs
> in allogeneic HCT discussion, autologous gene-cell therapy discussion,
> non-curative disease modification, standard-care stabilization first, or
> benchmark-only tracking?

## Boundary

This gate does not provide diagnosis, dosing, treatment selection, eligibility,
trial-screening instruction, referral, travel guidance, import guidance,
purchase guidance, transfusion change, chelation change, lab contact, private
message routing, or sample-routing permission.

Quran 49:6 and 4:58 are process-ethics anchors only. They support verification
and qualified owner routing, not biomedical claims.

## Sources

- [June 25 source JSON](../../../data/literature/pubmed/2026-06-25-branch-review-minimum-packet-refresh.json)
- [June 25 workflow JSON](../../../data/workflows/case-001/2026-06-25-branch-review-minimum-packet-gate.json)
- [TIF 2025 diagnosis chapter](https://www.ncbi.nlm.nih.gov/books/NBK614253/)
- [TIF 2025 blood transfusion chapter](https://www.ncbi.nlm.nih.gov/books/NBK614240/)
- [TIF 2025 iron overload chapter](https://www.ncbi.nlm.nih.gov/books/NBK614244/)
- [TIF 2025 monitoring recommendations](https://www.ncbi.nlm.nih.gov/books/NBK614248/)
- [TIF 2025 HCT chapter](https://www.ncbi.nlm.nih.gov/books/NBK614242/)
- [TIF 2025 gene manipulation chapter](https://www.ncbi.nlm.nih.gov/books/NBK614241/)
- [PubMed PMID 40058646](https://pubmed.ncbi.nlm.nih.gov/40058646/)
- [PubMed PMID 42274009](https://pubmed.ncbi.nlm.nih.gov/42274009/)
- [PubMed PMID 42091200](https://pubmed.ncbi.nlm.nih.gov/42091200/)
- [PubMed PMID 42252696](https://pubmed.ncbi.nlm.nih.gov/42252696/)
- [Quran 49:6 anchor](../../islamic/quran/049-al-hujurat/006.md)
- [Quran 4:58 anchor](../../islamic/quran/004-an-nisa/058.md)
